Ginkgo Bioworks (NYSE:DNA), Inc. is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.
The company’s services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing. Ginkgo collaborates with partners in pharmaceuticals, agriculture, food and beverage, cosmetics and materials, helping clients replace petroleum-based or less sustainable processes with biologically based alternatives. Its platform approach allows for parallelized workflows, enabling rapid iteration and reducing time-to-market for novel products.
Founded in 2008 by a team of MIT-trained scientists, Ginkgo Bioworks is headquartered in Boston, Massachusetts. Over the years, the company has expanded its footprint with additional laboratories and foundry facilities in the United States and Europe. Under the leadership of co-founder and CEO Jason Kelly, Ginkgo has grown its platform capabilities through strategic partnerships and acquisitions, broadening its service offerings and strengthening its position in the synthetic biology sector.
Ginkgo Bioworks continues to focus on scaling its technology and building an ecosystem of collaborators. By bringing together expertise in biology, engineering and software, the company aims to unlock new applications for living organisms, driving innovation in sustainability and bio-manufacturing on a global scale.
